### SLE

#### Assessment
- Evaluate for underlying lupus-related organ damage that may affect pregnancy risk
- Check anti-Ro/SSA and/or anti-La/SSB antibodies once pre- or early pregnancy
- Check aPL (aCL, aβ2GPI, LAC) once pre- or early pregnancy

#### Management
- Before pregnancy, stop CYC, MMF, or thalidomide 1-3 months prior to attempting conception
- Allow adequate time after medication transition to assess efficacy of new therapy before conceiving

### Inflammatory Arthritis

#### Assessment
- In patients with RA or JIA check anti-Ro/SSA and/or anti-La/SSB antibodies once pre- or early pregnancy
- Evaluate joint range of motion that may affect ability to delivery vaginally (hips) or to undergo emergency intubation (cervical spine)

#### Management
- Continue pregnancy-compatible medications.
- Stop methotrexate 1-3 months prior to attempting conception; stop leflunomide, test serum levels and treat with cholestyramine washout if necessary**
- Use prednisone sparingly
- Continue or restart breastfeeding compatible medication promptly after delivery to prevent a post-partum flare

### Scleroderma

#### Assessment
- Evaluate for underlying scleroderma-related organ damage that may affect pregnancy risk

#### Management
- Continue pregnancy-compatible medications to control disease
- Monitor for scleroderma renal crisis; treat with ACE-I or ARB if it occurs

### Vasculitis, myositis and other RMD

#### Assessment
- Evaluate for underlying vasculitis-related organ damage that may affect pregnancy risk

#### Management
- Continue pregnancy-compatible medications to control disease
- Use prednisone sparingly

---

*All diseases should be evaluated for disease activity at the time of initial assessment and then monitored for RMD disease activity during management

**If possible IgG-based TNF-inhibitors should be stopped in the early 3rd trimester to limit placental transfer
aCL: anticoardiolipin antibody  
aβ2GPI: anti-beta2 Glycoprotein I antibody  
LAC: lupus anticoagulant  
CYC: cyclophosphamide  
MMF: mycophenolate mofetil (or mycophenolic acid)  
ACE-I: angiotensin converting enzyme – inhibitor  
ARB: Angiotensin II receptor blocker